The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

25, 2024 — Adults with hemophilia ... mutations in microRNA, by ... Researchers Discover Potential Mole Reversal Therapy in Rare Condition June 17, 2024 — Researchers have designed a new ...

Spanish authorities issued a positive recommendation for national reimbursement of Hemgenix gene therapy for eligible ...

Single-Dose Gene Therapy Is Potentially Life-Changing for Adults With Hemophilia B Sep. 25, 2024 — Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71 percent ...

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) are working on a ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

Hemophilia B is a genetic disorder that affects how well your blood clots. Treatment includes supplementing the protein factor IX, but new therapies may offer alternative ways to manage factor IX ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...